ADMA BIOLOGICS INC

ADMA stock represents shares of ADMA Biologics, Inc., a biopharmaceutical company listed on the Nasdaq under the ticker ADMA. The company focuses on developing, manufacturing, and commercializing plasma-derived biologic products for patients with immune deficiencies and infectious diseases. Its lead products include intravenous immune globulin (IVIG) therapies. Investors tracking ADMA stock are typically following a specialty biotech with commercial-stage operations and a focus on the plasma product market.

Recent performance for ADMA depends on the latest market session, so the most accurate figures are shown in the price chart and performance data on this page. Investors often review the day's change, intraday range, and trailing periods such as one-month, three-month, and year-to-date returns. These snapshots can help put the stock's recent movement in context relative to broader market and sector trends. Refer to the live ADMA quote for up-to-date performance.

Valuing ADMA involves examining metrics such as price-to-sales, price-to-earnings, and enterprise value multiples, alongside its growth trajectory and profitability. Since biopharmaceutical companies can have uneven earnings, revenue-based and cash-flow-based measures may be more informative than a single P/E ratio. Comparing ADMA's multiples with peers in the biotech or plasma-products space can offer perspective. Always review the latest reported financials and the valuation figures displayed on this page for current data.

ADMA Biologics has historically not paid a regular cash dividend, directing its capital toward research, manufacturing, and commercial expansion instead. For companies in the biotech sector, reinvesting profits into growth is common. If ADMA's dividend policy changes, the details would appear in the dividend section of this page. Investors interested in income should confirm the current dividend status using the latest ADMA company data rather than relying on past practice.

Key risks for ADMA include regulatory and clinical setbacks, manufacturing or supply-chain disruptions for plasma products, competition from larger biopharma firms, and reliance on a limited number of products for revenue. Changes in reimbursement or healthcare policy could also affect demand. Like other small- and mid-cap biotechs, ADMA can be sensitive to volatility and financing conditions. These factors make it important to review risk disclosures and the latest filings before making any investment decision.

Analyzing ADMA's financials involves reviewing its income statement, balance sheet, and cash flow statement. Look at revenue growth, gross and operating margins, net income trends, and cash burn or generation. For a commercial-stage biotech, product revenue mix and gross margin can be especially telling. Also check liquidity, debt levels, and any guidance in earnings reports. The financial statements and metrics available on this page provide the latest reported figures for ADMA.